BioNTech to Present Clinical Data Updates Across mRNA and Immunomodulatory Oncology Portfolio at ESMO Congress 2024
September 05, 2024 07:15 ET
|
BioNTech SE
MAINZ, Germany, September 05, 2024 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present clinical trial data for selected assets from its multi-platform oncology pipeline at the...
Marugame Udon fuels U.S. expansion with Bikky’s customer analytics
September 04, 2024 08:00 ET
|
Bikky Inc.
NEW YORK, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Bikky, a customer data platform built exclusively for multi-unit restaurants, today announced a partnership with Marugame Udon USA, the fast-casual...
Three Complete Responses in Azer-Cel Allogeneic CD19 CAR T Phase 1b Trial in Blood Cancer (Diffuse Large B-Cell Lymphoma)
September 03, 2024 08:30 ET
|
Imugene Limited
Three complete responses in azer-cel allogeneic CD19 CAR T Phase 1b trial in blood cancer (Diffuse Large B-Cell Lymphoma)
ProKidney Announces Strategic Updates to its Phase 3 Program to Accelerate Rilparencel’s Registrational Path to Potential Approval in the U.S.
September 03, 2024 07:30 ET
|
ProKidney
Refined the focus of the Phase 3 program to accelerate path to potential U.S. approval and commercial launch in the Company’s highest priority marketDiscontinued the ex-U.S.-based PROACT 2 trial and...
Nuvectis Pharma Announces Orphan Drug Designation Granted by the FDA for NXP800 for the Treatment of ARID1a-deficient Ovarian, Fallopian Tube, and Primary Peritoneal Cancers
August 29, 2024 08:00 ET
|
Nuvectis Pharma, Inc.
FORT LEE, N.J., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) (“Nuvectis” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of...
Jeune Aesthetics Announces Phase 1 Positive Interim Safety and Efficacy Results for KB301 in the Treatment of Lateral Canthal Lines and Dynamic Wrinkles of the Décolleté
August 28, 2024 07:00 ET
|
Krystal Biotech, Inc.
Décolleté indication selected for Phase 2 study expected to start next year Conference call to discuss results scheduled for Wednesday, August 28, 2024 at 4:30 p.m. ET PITTSBURGH, Aug. 28, 2024...
SoftServe Releases Gen AI Solutions Accelerated with NVIDIA NIM™ Agent Blueprints
August 27, 2024 09:01 ET
|
SoftServe
AUSTIN, Texas, Aug. 27, 2024 (GLOBE NEWSWIRE) -- SoftServe, a premier IT consulting and digital services provider, today announced the first release of SoftServe Gen AI Solutions accelerated with...
RTI Awarded $1.25M to Advance Generative AI Research for the United States Department of Air Force
August 27, 2024 08:00 ET
|
Real-Time Innovations (RTI)
Real-Time Innovations (RTI) has been awarded a $1.25 million Small Business Innovation Research (SBIR) Phase II contract.
Autolus Therapeutics Presents Clinical Data Update at the Society of Hematologic Oncology (SOHO) Annual Meeting 2024
August 27, 2024 07:00 ET
|
Autolus Therapeutics plc
Autolus presents clinical data update at the Society of Hematologic Oncology (SOHO) Annual Meeting 2024
Molecular Partners Reports H1 2024 Corporate Highlights and Financials
August 26, 2024 16:00 ET
|
Molecular Partners
First Radio-DARPin Therapy (RDT) candidate MP0712 nominated; supporting preclinical package presented at SNMMI; initial clinical data expected in 2025 Strategic collaboration agreement signed with...